Roche hands over an­oth­er batch of pos­i­tive PhI­II da­ta on its new flu drug, look­ing for an ear­ly-win­ter launch

Roche has tak­en an­oth­er big stride to­ward gain­ing ap­proval for its new flu ther­a­py — eye­ing a mar­ket launch just as win­ter is set to get se­ri­ous.

We don’t have any da­ta, but their sec­ond Phase III tri­al need­ed for a US OK has come through pos­i­tive on the pri­ma­ry as well as sev­er­al sec­ondary end­points. And the re­sults come on top of its ini­tial suc­cess, which laid the foun­da­tion for its reg­u­la­to­ry pack­age at the agency, slat­ed to de­liv­er an ac­cel­er­at­ed de­ci­sion by Christ­mas Eve.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.